BioNxt Solutions Announces Closing of Shares for Debt Settlement

Rhea-AI Summary

BioNxt Solutions (OTCQB:BNXTF) has completed a debt settlement transaction with an arm's length creditor. The company settled a total debt of $225,010 through a combination of share issuance and cash payment. The settlement included issuing 112,505 common shares at CAD$1.00 per share and making a cash payment of $112,505.

The issued shares are subject to a mandatory four-month and one-day holding period in compliance with CSE policies and Canadian securities regulations.

Positive

• Debt reduction of $225,010 through partial equity conversion
• Preservation of cash through 50% equity settlement of debt

Negative

• Dilution of existing shareholders through issuance of 112,505 new shares

VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news release of September 12, 2025, it has closed its debt settlement with an arm's length creditor (the "Creditor") related to an aggregate of $225,010 in debt (the "Debt") owing for services provided by the Creditor to the Company. In full satisfaction and settlement of the Debt, the Company issued an aggregate of 112,505 common shares in the capital of the Company (the "Debt Shares") at a deemed price of CAD$1.00 per Debt Share and made a cash payment of $112,505 to the Creditor (the "Debt Settlement").

The Debt Shares issued in connection with the Debt Settlement are subject to a statutory four month and one day hold period, in accordance with the policies of the Canadian Securities Exchange ("CSE") and applicable Canadian securities laws.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide.

BioNxt is listed on the Canadian Securities Exchange: BNXT, OTCQB Markets:BNXTF and trades in Germany under WKN:A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.

Investor Relations & Media Contact

Hugh Rogers, Co‐Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698

Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt‐solutions
Instagram: https://www.instagram.com/bionxt

THIS NEWS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF ANY OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL. THE DEBENTURES AND THE SHARES WHICH MAY BE ISSUED ON EXERCISE THEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS.

Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE: BioNxt Solutions Inc.

View the original press release on ACCESS Newswire

FAQ

What is the value of BioNxt Solutions' (BNXTF) recent debt settlement?

BioNxt Solutions settled a total debt of $225,010, with half paid in shares and half in cash.

How many shares did BioNxt Solutions (BNXTF) issue for the debt settlement?

BioNxt Solutions issued 112,505 common shares at a deemed price of CAD$1.00 per share.

What is the lock-up period for the shares issued in BioNxt's debt settlement?

The shares are subject to a four-month and one-day statutory hold period in accordance with CSE policies and Canadian securities laws.

How did BioNxt Solutions (BNXTF) structure the debt settlement payment?

The settlement was structured as a 50/50 split: $112,505 in shares and $112,505 in cash.